Somatostatin News and Research RSS Feed - Somatostatin News and Research

Chiasma closes $70 million Series E financing round

Chiasma closes $70 million Series E financing round

Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closing of a $70 million Series E financing round. [More]
Carnegie Mellon study identifies intermediary neuron system that acts as synaptic cloaking device

Carnegie Mellon study identifies intermediary neuron system that acts as synaptic cloaking device

Neuroscientists believe that the connectome, a map of each and every connection between the millions of neurons in the brain, will provide a blueprint that will allow them to link brain anatomy to brain function. But a new study from Carnegie Mellon University has found that a specific type of neuron might be thwarting their efforts at mapping the connectome by temporarily cloaking the synapses that link a wide field of neurons. [More]
Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for early release on Feb. 9, ahead of print, by the Journal of Clinical Endocrinology & Metabolism. [More]
Novel technique could help identify cancerous tissue during brain tumor surgery

Novel technique could help identify cancerous tissue during brain tumor surgery

A novel radioguided surgery technique could quickly and effectively identify residual cancer cells during brain tumor surgery, with low radiation exposure for both patients and surgeons. The study, featured in the January 2015 issue of the Journal of Nuclear Medicine, reports that Y-90 DOTATOC, a beta-minus-emitting tracer, can effectively delineate the margins of meningiomas and high-grade gliomas. [More]
Ipsen's Somatuline Depot Injection 120 mg receives FDA approval for treatment of GEP-NETs

Ipsen's Somatuline Depot Injection 120 mg receives FDA approval for treatment of GEP-NETs

Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, today announced that Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) was approved by the U.S. Food and Drug Administration for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve progression-free survival (PFS). [More]
Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. [More]
Researchers identify important neural mechanism responsible for certain chronic pain disorders

Researchers identify important neural mechanism responsible for certain chronic pain disorders

Pain typically has a clear cause-but not always. When a person touches something hot or bumps into a sharp object, it's no surprise that it hurts. But for people with certain chronic pain disorders, including fibromyalgia and phantom limb pain, a gentle caress can result in agony. [More]
Novel therapeutic approaches to improve thyroid cancer outcomes

Novel therapeutic approaches to improve thyroid cancer outcomes

Novel therapeutic approaches to improve outcomes in thyroid cancer, for example using targeted delivery of cytotoxic drugs to tumor cells, will be among the topics featured in oral and poster presentations delivered at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California. [More]
Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly is a chronic, life-threatening disease triggered by a benign tumour of the pituitary gland causing excessive growth hormone release. Oversupply of growth hormone stimulates liver, fat and kidney cells to produce excess levels of Insulin-Like Growth Factor I (IGFI), which causes abnormal growth of the bones of the hands, face and feet and bodily organs. [More]
Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

The U.S. affiliate of Ipsen today announced that the New England Journal of Medicine has published clinical trial results showing that Somatuline Autogel / Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) achieved statistically significant prolongation of progression free survival (PFS) over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). [More]
Ipsen submits Supplemental New Drug Application to FDA for Somatuline Depot 120mg injection

Ipsen submits Supplemental New Drug Application to FDA for Somatuline Depot 120mg injection

Ipsen today announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration for Somatuline Depot 120mg injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). [More]
Combined chemo and radionuclide therapy stops neuroendocrine tumors

Combined chemo and radionuclide therapy stops neuroendocrine tumors

Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. [More]
Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control. [More]
Professor receives 2014 Rolf Luft Award for research on diabetes and endocrinology

Professor receives 2014 Rolf Luft Award for research on diabetes and endocrinology

Dr. Roger Unger, Professor of Internal Medicine at UT Southwestern Medical Center has been awarded the 2014 Rolf Luft Award for his identification of glucagon as a pancreatic hormone that raises blood sugar levels, having the opposite effect of insulin. [More]
AAA gets orphan drug designation status for radiopharmaceutical, Gallium-68 DOTATATE

AAA gets orphan drug designation status for radiopharmaceutical, Gallium-68 DOTATATE

Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM), announced today that they have received orphan drug designation status for their radiopharmaceutical, Gallium-68 DOTATATE. [More]
Drugs often fail to bring acromegaly under control in routine clinical practice

Drugs often fail to bring acromegaly under control in routine clinical practice

Over a quarter of UK patients treated for growth hormone-producing tumours do not achieve 'safe' growth hormone levels, according to a 30 year UK multi-centre study of clinical management of the rare disease acromegaly. The findings by the Society for Endocrinology UK Acromegaly Register, published in the November issue of Clinical Endocrinology, show that drugs to control acromegaly often fail to bring the disease completely under control in routine clinical practice. [More]
Pancreatic protein essential for maintaining functional state of beta cells

Pancreatic protein essential for maintaining functional state of beta cells

Researchers at the Pediatric Diabetes Research Center (PDRC) at the University of California, San Diego School of Medicine have shown that the pancreatic protein Nkx6.1 - a beta-cell enriched transcription factor - is essential to maintaining the functional state of beta cells. [More]
Neuroscientists identify key circuit elements that contribute to everyday decision in ACC

Neuroscientists identify key circuit elements that contribute to everyday decision in ACC

You are sitting on your couch flipping through TV channels trying to decide whether to stay put or get up for a snack. Such everyday decisions about whether to "stay" or to "go" are supported by a brain region called the anterior cingulate cortex (ACC), which is part of the prefrontal cortex. [More]
Chiasma, Roche enter agreement to develop and commercialize Octreolin

Chiasma, Roche enter agreement to develop and commercialize Octreolin

Roche and Chiasma Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. [More]
Study examines how fear responses are learned, controlled and memorized

Study examines how fear responses are learned, controlled and memorized

A rustle of undergrowth in the outback: it's a sound that might make an animal or person stop sharply and be still, in the anticipation of a predator. That "freezing" is part of the fear response, a reaction to a stimulus in the environment and part of the brain's determination of whether to be afraid of it. [More]
Advertisement
Advertisement